Acquisitions6 Dec 2025, 10:21 am
Biocon to Integrate Biocon Biologics to Create a Unified Global Biopharmaceutical Leader
AI Summary
Biocon Limited, an innovation-led global biopharmaceuticals company, has announced a strategic corporate action to fully integrate Biocon Biologics Limited as a wholly owned subsidiary. The integration is expected to be completed by March 31, 2026, and will leverage the global commercial infrastructure, simplify the corporate structure, and strengthen Biocon’s global position in diabetes, oncology, and immunology. Shreehas Tambe will lead the combined business as CEO & Managing Director upon completion of the integration.
Key Highlights
- Biocon Limited to integrate Biocon Biologics Limited as a wholly owned subsidiary
- Integration expected to be completed by March 31, 2026
- Leveraging global commercial infrastructure and simplifying corporate structure
- Strengthening Biocon’s global position in diabetes, oncology, and immunology
- Shreehas Tambe to lead the combined business as CEO & Managing Director